Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752371 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Camoteskimab in Participants With Still's Disease
A Phase 1 study, sponsored by Apollo Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04752371 is a Phase 1 study that was terminated before completion, run by Apollo Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT04752371, a Phase 1 study, was terminated before completion, sponsored by Apollo Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
Interventions
- DRUG Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-03-25 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752371
The ClinicalTrials.gov registry entry for NCT04752371 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apollo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Camoteskimab (CERC-007, AVTX-007, AEVI-007) is the first listed.
NCT04752371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04752371 about?
NCT04752371 is a clinical study titled "A Study to Evaluate Camoteskimab in Participants With Still's Disease". The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
What is the current status of trial NCT04752371?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-03-25. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT04752371?
The interventions under investigation include: Camoteskimab (CERC-007, AVTX-007, AEVI-007) (DRUG).
Who is sponsoring clinical trial NCT04752371?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.